programma & abstracts - Nederlandse Vereniging voor Radiologie

5
programma abstracts & abstracts
O5.2
CLINICAL PERFORMANCE OF A NOVEL
BIOACTIVE COMPOSITE IN THE TREATMENT
OF VERTEBRAL COMPRESSION FRACTURES
R. Schepers-Bok 1 , M. Geerdes 1 , M.E. Havinga 1 , R. Aquarius 2 ,
P.J.W. Wensing 1
1
Ziekenhuisgroep Twente, Hengelo
2
Radboud University Nijmegen Medical Centre, Nijmegen
Objective: To analyse the outcome of percutaneous vertebroplasty
with CortossTM in patients with vertebral compression
fractures.
Methods: Between 2005 and 2010, 221 vertebral compression
fractures were treated with percutaneous vertebroplasty
in 132 patients. Inclusion criteria were: compression fractures
due to osteoporosis, trauma or malignancy, invalidating
back pain due to compression fracture, no improvement
to standard conservative therapy for minimal 6 weeks,
Numerical Rating Scale (NRS) score of at least 7 and bone
marrow edema on MRI scan.
NRS score was obtained before, and two and six weeks
after vertebroplasty. Primary outcome was pain reduction
measured by NRS score. Clinically significant pain relief
was defined as a decrease in NRS score of at least 3 points.
Secondary outcome were new vertebral fractures, injected
volume and complications.
Results: Two weeks after vertebroplasty, 84,7% of the
patients showed a decrease of at least three points on NRS
score. This increased to 86,8% after six weeks. 34 new fractures
occurred in 22 patients (17,4%).No embolisms occurred.
Mean injected volume of Cortoss was 1,54 mL.
Conclusion: In a group of patients with vertebral compression
fractures percutaneous vertebroplasty with Cortoss is
an effective and safe treatment option. PVP leads to a significant,
rapid decrease in pain. Our results are comparable
to results of other studies which used PMMA. These good
clinical results, together with advantages of Cortoss, such
as the low cement volume needed, and the mix-on-demand
delivery system, make it a strong candidate to be a standard
material in vertebral augmentation.
Figure 1: Distribution of Cortoss: trabecular pattern.
Table 1: Patient characteristics.
38
k i j k o o k o p w w w . c o n g r e s s c o m p a n y . c o m
o f w w w . r a d i o l o g e n . n l